Literature DB >> 25190749

Lenalidomide, an antiproliferative CLL drug.

Martina Seiffert1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25190749      PMCID： PMC4155263          DOI： 10.1182/blood-2014-07-587360

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Identification of a primary target of thalidomide teratogenicity.

Authors:  Takumi Ito; Hideki Ando; Takayuki Suzuki; Toshihiko Ogura; Kentaro Hotta; Yoshimasa Imamura; Yuki Yamaguchi; Hiroshi Handa
Journal:  Science       Date:  2010-03-12       Impact factor: 47.728

Review 2.  Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.

Authors:  Krzysztof Giannopoulos; Daniel Mertens; Stephan Stilgenbauer
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

3.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

4.  Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53.

Authors:  Jessie-F Fecteau; Laura G Corral; Emanuela M Ghia; Svetlana Gaidarova; Diahnn Futalan; Ila Sri Bharati; Brian Cathers; Maria Schwaederlé; Bing Cui; Antonia Lopez-Girona; Davorka Messmer; Thomas J Kipps
Journal:  Blood       Date:  2014-07-02       Impact factor: 22.113

5.  Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.

Authors:  Angela Schulz; Claudia Dürr; Thorsten Zenz; Hartmut Döhner; Stephan Stilgenbauer; Peter Lichter; Martina Seiffert
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

6.  PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex.

Authors:  Tarek Abbas; Uma Sivaprasad; Kenta Terai; Virginia Amador; Michele Pagano; Anindya Dutta
Journal:  Genes Dev       Date:  2008-09-15       Impact factor: 11.361

7.  Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.

Authors:  Alan G Ramsay; Amy J Johnson; Abigail M Lee; Güllü Gorgün; Rifca Le Dieu; William Blum; John C Byrd; John G Gribben
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

8.  The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.

Authors:  Gang Lu; Richard E Middleton; Huahang Sun; MarkVic Naniong; Christopher J Ott; Constantine S Mitsiades; Kwok-Kin Wong; James E Bradner; William G Kaelin
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

9.  IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia.

Authors:  Ilaria Iacobucci; Nunzio Iraci; Monica Messina; Annalisa Lonetti; Sabina Chiaretti; Emanuele Valli; Anna Ferrari; Cristina Papayannidis; Francesca Paoloni; Antonella Vitale; Clelia Tiziana Storlazzi; Emanuela Ottaviani; Viviana Guadagnuolo; Sandra Durante; Marco Vignetti; Simona Soverini; Fabrizio Pane; Robin Foà; Michele Baccarani; Markus Müschen; Giovanni Perini; Giovanni Martinelli
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

10.  Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).

Authors:  Anita K Gandhi; Jian Kang; Courtney G Havens; Thomas Conklin; Yuhong Ning; Lei Wu; Takumi Ito; Hideki Ando; Michelle F Waldman; Anjan Thakurta; Anke Klippel; Hiroshi Handa; Thomas O Daniel; Peter H Schafer; Rajesh Chopra
Journal:  Br J Haematol       Date:  2013-12-13       Impact factor: 6.998
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.